Clinical Trial Update: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating upfront afatinib with concurrent chemotherapy followed by osimertinib with concurrent chemotherapy in untreated EGFR-positive non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (afatinib) (afatinib)
• Tagrisso (osimertinib) (osimertinib)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED